ADMA Biologics (NASDAQ:ADMA) Lowered to Hold (C+) Rating by Weiss Ratings

Key Points

• ADMA Biologics has been downgraded by Weiss Ratings from a "buy (b-)" to a "hold (c+)" rating, indicating a shift in analysts' confidence in the stock.
• The company reported earnings of $0.15 per share for the last quarter, slightly exceeding analysts' expectations and demonstrating a 13.8% increase in revenue from the previous year.
• Institutional investors hold 75.68% of ADMA's stock, with recent increases in stakes from firms such as Cullen Frost Bankers and Smartleaf Asset Management.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) was downgraded by analysts at Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating in a research note issued on Friday,Weiss Ratings reports.

ADMA Biologics Stock Performance

ADMA traded up $0.76 on Friday, reaching $16.01. The company had a trading volume of 2,024,886 shares, compared to its average volume of 3,160,995. The company's fifty day moving average is $15.85 and its 200 day moving average is $18.26. ADMA Biologics has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The stock has a market cap of $3.82 billion, a P/E ratio of 18.63 and a beta of 0.47. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the prior year, the business posted $0.13 EPS. The business's revenue was up 13.8% compared to the same quarter last year. As a group, analysts predict that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Salomon & Ludwin LLC bought a new stake in ADMA Biologics in the third quarter valued at $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in ADMA Biologics in the first quarter valued at $35,000. SVB Wealth LLC bought a new stake in ADMA Biologics in the first quarter valued at $35,000. Cullen Frost Bankers Inc. grew its holdings in shares of ADMA Biologics by 112.5% during the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company's stock valued at $37,000 after buying an additional 1,081 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of ADMA Biologics by 161.4% during the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after buying an additional 1,493 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.